Literature DB >> 21726836

Comparison of differential expression of P2Y₁₂ receptor in culprit coronary plaques in patients with acute myocardial infarction versus stable angina pectoris.

Cheol Whan Lee1, Ilseon Hwang, Chan-Sik Park, Hyangsin Lee, Duk-Woo Park, Su-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Seong-Wook Park, Seung-Jung Park.   

Abstract

P2Y₁₂ receptor antagonists may have pleiotropic benefits. Little is known, however, about the expression of P2Y₁₂ receptors in coronary atherosclerotic plaques. We investigated the expression of P2Y₁₂ receptor in coronary atherectomy tissues retrieved from patients with acute myocardial infarction (AMI) or stable angina pectoris (SAP). Tissue specimens were collected from 35 patients with AMI and 19 with SAP who underwent directional coronary atherectomy. Specimens were analyzed immunohistochemically using antibodies specific to P2Y₁₂ receptor and to markers of endothelial cells, macrophages, and smooth muscle cells. The 2 groups had similar baseline clinical characteristics. Plaque types were more likely to be cellular in the AMI group. The proportion of areas immunopositive for α-smooth muscle actin was smaller but those positive for CD31 and CD68 were larger in the AMI than in the SAP group. In addition, the relative area immunopositive for P2Y₁₂ receptor was significantly larger for AMI than SAP (1.1 ± 0.9% vs 0.5 ± 0.4%, respectively, p < 0.001). P2Y₁₂ receptor positivity coincided with areas positive for CD31 and α-smooth muscle actin. In conclusion, P2Y₁₂ receptor is present in coronary atherosclerotic plaques and is increased in culprit plaques of patients with AMI. P2Y₁₂ receptor may play a role in plaque destabilization.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726836     DOI: 10.1016/j.amjcard.2011.05.008

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

2.  Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation.

Authors:  Minyoung Oh; Cheol Whan Lee; Hyo Sang Lee; Mineok Chang; Jung-Min Ahn; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Dae Hyuk Moon; Seong-Wook Park; Seung-Jung Park
Journal:  Clin Cardiol       Date:  2016-07-26       Impact factor: 2.882

3.  ADP-induced bladder contractility is mediated by P2Y12 receptor and temporally regulated by ectonucleotidases and adenosine signaling.

Authors:  Weiqun Yu; Xiaofeng Sun; Simon C Robson; Warren G Hill
Journal:  FASEB J       Date:  2014-09-10       Impact factor: 5.191

4.  Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation.

Authors:  Shabnam Salimi; Joshua P Lewis; Laura M Yerges-Armstrong; Braxton D Mitchell; Faisal Saeed; Jeffry R O'Connell; James A Perry; Kathleen A Ryan; Alan R Shuldiner; Afshin Parsa
Journal:  J Am Heart Assoc       Date:  2016-10-31       Impact factor: 5.501

5.  Comparison of the Infarct Size between the Loading of Ticagrelor and Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Kyeong Ho Yun; Sang Jae Rhee; Jum Suk Ko
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

6.  Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction.

Authors:  Zahra Lotfollahi; Ana P Q Mello; Francisco A H Fonseca; Luciene O Machado; Andressa F Mathias; Maria C Izar; Nagila R T Damasceno; Cristiano L P Oliveira; Antônio M F Neto
Journal:  PLoS One       Date:  2022-08-30       Impact factor: 3.752

Review 7.  P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation.

Authors:  Alexandre Mansour; Christilla Bachelot-Loza; Nicolas Nesseler; Pascale Gaussem; Isabelle Gouin-Thibault
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.